Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2023-08-18 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
2023年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2023 年半年度报告摘要" which translates to "2023 Semi-Annual Report Summary." It contains detailed financial data for the half-year period, including revenue, net profit, cash flow, shareholder information, and operational highlights. The document includes comprehensive financial metrics, business updates, R&D activities, marketing, production, and social responsibility efforts. The length is over 12,000 characters, indicating a substantive report rather than a brief announcement. The content matches the characteristics of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year and contains actual financial statements and analysis. Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2023
2023-08-18 Chinese
2023年上半年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 95% confidence The document is a detailed summary table of non-operating fund occupation and other related party fund transactions for the first half of 2023 by 健帆生物科技集团股份有限公司. It includes financial figures, related party names, accounting subjects, and balances as of June 30, 2023. The document is signed and approved by the board and company officers. The content is a financial summary related to internal fund usage and related party transactions for a half-year period, but it is not a full interim or quarterly report with comprehensive financial statements. It is more of a regulatory disclosure or summary of related party transactions and fund occupation. The document length is 2633 characters, which is relatively short and focused on a specific financial disclosure. This fits best under Regulatory Filings (RNS), as it is a compliance disclosure of related party transactions and fund occupation, not a full financial report or earnings release.
2023-08-18 Chinese
2023年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "健帆生物科技集团股份有限公司 2023 年半年度报告全文" which translates to "Jafron Biomedical Co., Ltd. 2023 Semi-Annual Report Full Text." It includes detailed sections such as company overview, financial data, management discussion and analysis, governance, social responsibility, important matters, shareholder information, bond information, and financial statements. The document length is about 15,000 characters, indicating a comprehensive report rather than a brief announcement. The content includes actual financial figures, management analysis, business overview, and detailed operational data for the half-year period of 2023. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing substantive financial data and analysis. Therefore, the document is classified as an Interim / Quarterly Report (IR). H1 2023
2023-08-18 Chinese
2023年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2023 Half-Year Special Report on the Deposit and Actual Use of Raised Funds" by the company. It details the amount of funds raised through convertible bonds, the use and balance of these funds, the management and storage of the funds, and the status of investment projects funded by these raised funds. It references regulatory guidelines on the management and use of raised funds and includes detailed financial figures and tables about the raised funds usage for the half-year period ending June 30, 2023. The document is a specialized report focused on the management and use of capital raised by the company, specifically related to fundraising activities and the deployment of those funds. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is not a full annual or interim report, nor is it an earnings release or audit report. It is not a simple announcement of a report but contains substantive financial data and analysis about the use of raised funds. Therefore, the appropriate classification is CAP.
2023-08-18 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of the company regarding the approval of the 2023 half-year (interim) report and a special report on the use of raised funds. It states that the reports were reviewed and approved, and refers readers to the full reports published on the official disclosure website. The document itself does not contain the actual financial statements or substantive financial data, but rather announces the approval and availability of these reports elsewhere. The document length is short (932 characters), and it primarily serves as an announcement of the report's approval and publication, not the report itself. Therefore, according to the MENU VS MEAL RULE, this should be classified as a Regulatory Filing (RNS) rather than an Interim Report (IR).
2023-08-18 Chinese
董事会决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the seventh meeting of the fifth board of directors of the company. It specifically mentions the approval of the 2023 semi-annual report and its summary, as well as a special report on the use of raised funds. The document states that the actual reports are published on the official disclosure website and provides a link. The document itself does not contain the full semi-annual report or detailed financial data but is an announcement of the board meeting decisions and references the reports published elsewhere. The document length is short (981 characters), consistent with an announcement rather than a full report. Therefore, this document fits best as a Regulatory Filing (RNS) since it is a formal regulatory announcement of board resolutions and report approvals without containing the full report itself.
2023-08-18 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.